الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 155 |  |  |
| | | from | 155 | | |
Abstract
The role of neoadjuvant chemoradiotherapy in the treatment of patients with esophageal or esophagogastric-junction cancer is accepted now as a standard of care. However, its efficacy in comparison to perioperative chemotherapy treatment in locally advanced gastric carcinoma is still not well established. Preoperative CCRT with paclitaxel-carboplatin is accepted as a neoadjuvant treatment in GEJ adenocarcinoma with good efficacy and less adverse effects. This study is a phase II trial which included patients with locally advanced non metastatic gastro-esophageal and gastric adenocarcinoma, the enrolled patients received one cycle of induction chemotherapy paclitaxel-carboplatin, (paclitaxel at a dose of 175 mg/m2, carboplatin at dose of (AUC: 5), followed by CCRT with the same regimen, but with a lower dose (45 Gy concurrent with weekly paclitaxel at dose of 50 mg/m2, carboplatin at dose of (AUC: 2), followed by surgery then another 2 cycles of postoperative paclitaxel-carboplatin for the responders. The study included twenty-four patients with pathologically confirmed adenocarcinoma, who presented to Clinical Oncology & Nuclear Medicine Department, Mansoura University Hospital during the period from the start of January 2018 to the end of May 2019. The most common involved sites were GEJ and gastric cardia (87.5 %). Most of our patients were diagnosed at stage III (83.3 %). There were no major side effects for the induction chemotherapy cycle. For CCRT induced complication, there were no reported grade 3 or 4 toxicities. There were only two patients who suffered from late radiation toxicities in the form of dista.